NCT00717860 is a Phase 3 clinical trial of caspofungin acetate in Fungal Infection, sponsored by Merck Sharp & Dohme LLC.

Who is sponsoring NCT00717860?

NCT00717860 is sponsored by Merck Sharp & Dohme LLC.

What drugs are being tested in NCT00717860?

Interventions in NCT00717860: caspofungin acetate, Comparator: Micafungin sodium.

What condition does NCT00717860 study?

NCT00717860 studies Fungal Infection.

Is NCT00717860 still recruiting?

NCT00717860 is currently completed. Last updated 20 February 2017.

Are results published for NCT00717860?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2017-02-20 · How we verify

NCT00717860

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multicenter, Double-Blind, Comparative Study of MK0991 (Caspofungin) Versus Micafungin in Adult Japanese Patients With Deep-seated Candida or Aspergillus Infections

Completed Phase 3 Results posted Last updated 20 February 2017

What this trial tests

Phase 3 trial testing caspofungin acetate in Fungal Infection in 121 participants. Completed in 1 July 2010.

Timeline

1 August 2008

Primary endpoint
1 July 2010

1 July 2010

Quick facts

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	121
Start date	1 August 2008
Primary completion	1 July 2010
Estimated completion	1 July 2010

Drugs / interventions tested

caspofungin acetate — full drug profile →
Comparator: Micafungin sodium — full drug profile →

Conditions studied

Fungal Infection — all drugs for Fungal Infection →

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

20 and older, any sex, with Fungal Infection. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Participants With a Significant Drug-related Adverse Experience
Time frame: 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis
A significant drug-related adverse experience was defined as a serious drug-related adverse experience or a drug-related adverse experience leading to study therapy discontinuation.

Sponsor's own description

The purpose of this study is to investigate the safety and efficacy of MK0991 in patients with deep-seated mycoses.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis.
Kohno S, Izumikawa K, Yoshida M, Takesue Y, et al · · 2013 · cited 55× · PMID 23052987 · DOI 10.1007/s10096-012-1754-z

Verify or expand the search:

Other recruiting trials for Fungal Infection

Currently open trials in the same condition.

NCT07238114 — Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors · active not recruiting
NCT06510699 — Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial · Phase 2 · recruiting
NCT05814432 — Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS · Phase 3 · recruiting
NCT03717623 — Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants · Phase 4 · recruiting
NCT03828773 — PTX3-targeted Antifungal Prophylaxis · NA · recruiting

Other Merck Sharp & Dohme LLC trials

Trials by the same sponsor.

NCT07224477 — A Clinical Study of V540A in Healthy Female Participants (V540A-005) · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07528508 — A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527 · Phase 1 · not yet recruiting
NCT07513376 — A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (M · Phase 3 · not yet recruiting
NCT07532304 — A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Parti · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00717860 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merck Sharp & Dohme LLC
Last refreshed: 20 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00717860.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing